Endovascular intervention is emerging as a substitute for open surgical procedures for the treatment of cerebrovascular disease. However, up to 9% of patients undergoing neurointerventional procedures develop thromboembolic complications. Strategies to reduce periprocedural thromboembolic events are dominated by the use of dual antiplatelet therapy (DAT) which has been validated based on studies of peripheral vascular and coronary intervention. Of note, DAT decreases adverse vascular outcomes by 75-80% in patients undergoing percutaneous coronary intervention (PCI). It follows that similar treatment effects would be observed in neurointerventional populations. However, a growing body of evidence demonstrates that a subgroup of patients respond suboptimally to DAT, and in particular to clopidogrel (termed clopidogrel hyporesponders). These patients may be at an increased risk of thromboembolic complications such as in-stent thrombosis following neurointerventional procedures. Previous studies report 5-30% suboptimal response to clopidogrel in the cardiovascular population, while a higher prevalence is seen in populations undergoing neurointerventional procedures, i.e. as much as 66%. Knowledge of the mechanism leading to clopidogrel hyporesponsiveness is accumulating. A number of genetic polymorphisms, in particular CYP 2C19 * 2, have been associated with clopidogrel hyporesponsiveness and clinical outcomes. In addition, there are significant differences in the prevalence of CYP 2C19 * 2 across racial groups. Approximately 50% of Asians and 25% of Caucasians harbor the CYP 2C19 * 2 allele. While no prospective randomized
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Dual Antiplatelet Therapy in Coronary Intervention
Trials of dual antiplatelet therapy (DAT) have confirmed the benefit of clopidogrel in addition to aspirin compared to aspirin monotherapy in prevention of death, myocardial infarction (MI), and stroke in cardiovascular patients undergoing percutaneous coronary intervention (PCI) [3] . A trial of more than 1,600 patients across 50 centers undergoing coronary stent placement found that DAT (325 mg aspirin daily plus 250 mg ticlopidine twice daily) reduced the rate of stent thrombosis from 3.6% in the aspirin monotherapy group (325 mg once daily) to 0.6% in the DAT group [3] . Additionally, the authors reported a 75-80% relative risk reduction of cardiovascular death, MI, and stroke with the use of DAT.
DAT in Neurointerventional Procedures
To date, there are no randomized controlled trials in the neurointerventional patient population to demonstrate the benefits of DAT in reducing procedure-associated thromboembolic complications. Consequently, no well-established clinical guidelines exist to guide the use of DAT in this population. However, on the basis of randomized controlled trials in cardiology and expert opinion, the World Federation of Interventional and Therapeutic Neuroradiology (WFITN) has issued recommendations for DAT in the neurointervention setting. It is recommended that patients undergoing neurointerventional procedures receive aspirin 100 mg and clopidogrel 75 mg for 3 days prior to the procedure, with treatment duration to vary according to the nature of the intervention (www.wftin.org).
Recurrent Ischemic Events Despite DAT
Despite the obvious benefits of DAT in preventing thromboembolic complications after interventional procedures, there is a subpopulation of patients who develop recurrent ischemic events despite receiving therapeutic doses of antiplatelet agents. A review of trials in-vestigating the efficacy and safety of stent-assisted coiling as treatment for intracranial aneurysms reported that 6% of patients experienced clinically significant thromboembolic events while on DAT [4] . Authors of the CREST trial compared a variety of DAT regimens in patients undergoing carotid stenting or endarterectomy. Patients in the stenting arm had a rate of recurrent stroke or death of 6.8% at 4 years [5] .
Increasing awareness of the subpopulation of patients continuing to suffer ischemia despite therapeutic DAT has led to significant research into the phenomenon of antiplatelet hyporesponsiveness. Patients diagnosed as aspirin and/or clopidogrel hyporesponders have a lower than expected biological response to a therapeutic dose of an antiplatelet drug.
Variable Responsiveness to Clopidogrel
Clopidogrel hyporesponsiveness is an increasingly recognized clinical phenomenon. Platelet responsiveness following a therapeutic dose of clopidogrel is suggested to follow a bell curve distribution [6] . A secondary post hoc analysis involving a variety of patient subgroups revealed a mean percent platelet inhibition of 41.9% following a standard dose of clopidogrel as measured by light transmission aggregometry [6] . Defining clopidogrel hyperor hyporesponsiveness as a platelet inhibition 2 SD above or below the mean, respectively, patients with more than 45% or less than 37% platelet inhibition following a standard dose of clopidogrel were considered to be hyper-and hyporesponders, respectively [6] . Studies of cardiovascular patient populations suggest the prevalence of clopidogrel hyporesponsiveness to be between 5 and 30% [1] while current estimates indicate that the prevalence may be as high as 66% in patients undergoing neurointerventional procedures [7, 8] . In part, variation in prevalence rates of clopidogrel hyporesponsiveness may be due to differing methodologies for its diagnoses.
Clinical Implications of Clopidogrel Hyporesponsiveness
Hyporesponsiveness to clopidogrel is translated into a significant clinical risk of ischemic events. Meta-analysis and other studies reveal hyporesponsiveness to clopidogrel as an independent risk factor associated with an increased risk of cardiac, cerebrovascular, and peripheral atherothrombotic events [9] . Further, it has recently been demonstrated that clopidogrel hyporesponders are at an increased risk of periprocedural stent thrombosis following interventional surgery. A study of 1,019 patients undergoing PCI and receiving a bare metal stent (72.7% of study population) or drug-eluted stent (DES) (27.3% of study population) found 32.3% to be hyporesponsive to clopidogrel 6 h after a 600-mg loading dose as measured by light transmission aggregometry . At 3 months, 4.6% of clopidogrel hyporesponders had developed a stent thrombosis compared to 2% of responders (OR 2.31, 95% CI 1.1-4.84, p = 0.02) [10] . These findings appear to hold true for patients undergoing neurointerventions [7, 11, 12] . A study of 53 Korean patients undergoing neurointerventional procedures revealed that 62.3% were hyporesponsive to clopidogrel 3 days after initiation of 75 mg/day clopidogrel. Of note, 5 patients experienced thromboembolic complications after surgery, and all of them were hyporesponsive to clopidogrel with a mean percent platelet inhibition of ! 23% 8 2.3 [11] . To date, studies of clopidogrel hyporesponsiveness in the neurointervention patient population remain underpowered with small sample sizes. Research findings need to be replicated in larger cohorts to verify results.
Following increased awareness of the clinical risk associated with clopidogrel hyporesponsiveness, research attention is now focused on its potential causes.
Mechanisms of Clopidogrel Hyporesponsiveness
Variation in platelet responsiveness to clopidogrel may arise from alterations in its pharmacokinetic or pharmacodynamic actions as a result of genetic or nongenetic influences. Factors such as age, body mass index (BMI), and comorbidities such as diabetes can influence the pharmacokinetic and dynamic response to clopidogrel [9] . It is important to recognize that clopidogrel hyporesponsiveness can be an expression of medication nonadherence and medication interaction. An example is the interaction with proton pump inhibitors involved in the pharmacokinetic and pharmacodynamic actions of clopidogrel, which may play a role in the development of hyporesponsiveness. Genes involved in clopidogrel absorption (ABCB1), biotransformation (CYP 1A2, CYP 2B6, CYP 2C19, CYP 2C9, CYP 3A4, and CYP 3A5), and pharmacodynamic response (P2Y12) have been investigated [13] . Genetic polymorphisms in these genes have been studied to varying degrees, with some appearing not to play a role in platelet responsiveness (P2Y12 and CYP 1A2 polymorphisms) while the role of other polymorphisms remains contentious (CYP 3A5, 3A4, 2B6 and 2C9) [13] . Polymorphisms of the ABCB1 gene appear to be associated with clopidogrel responsivenesscompared with wild-type (genotype CC) carriers of 1 or 2 ABCB1 C3435T single-nucleotide polymorphisms have significantly reduced clopidogrel bioavailability following a 300-or 600-mg loading dose and poorer cardiovascular outcomes at 1 year post-MI [13] . However, the most consistent genetic polymorphisms associated with clopidogrel responsiveness and adverse clinical outcomes are polymorphisms of the CYP 2C19 gene.
Function and Prevalence of CYP 2C19 Polymorphisms
CYP 2C19 plays an important role in the biotransformation of clopidogrel. Clopidogrel is a thiopyridine antiplatelet agent requiring biotransformation into its active form by hepatic CYP isoenzymes. In the order of 85% of a standard dose of clopidogrel is inactivated via hepatic esterases, with the remaining 15% converted into the active thiol metabolite. In a first step, the inactive prodrug is converted into an inactive intermediate metabolite and in a subsequent second step into its active thiol metabolite. CYP 2C19 is responsible for approximately 45% of first step and 20% of second step reactions. Several polymorphisms of CYP 2C19 have been identified, each conferring a different level of enzyme activity. The CYP 2C19 * 1 polymorphism is considered to confer 'normal' enzyme activity while CYP 2C19 * 2 and * 3 render a nonfunctional enzyme. CYP 2C19 * 2 and * 3 polymorphisms comprise 85 and 99% of loss of function alleles in Caucasian and Asian populations, respectively [14] . The CYP 2C19 * 2 allele has approximately twice the prevalence in Asian populations compared to Caucasians; approximately 50% of Chinese and 25% of Caucasians carry at least one copy of the polymorphism [15] .
CYP 2C19 * 2 Influences Response to Clopidogrel
Genome-wide analysis has revealed that up to 12% of variation in platelet responsiveness is attributable to CYP 2C19 * 2 polymorphisms [16] . Cohort studies have demonstrated poorer platelet inhibition in carriers of the CYP 2C19 * 2 polymorphism compared to noncarriers [17] . A genetic dose effect is seen whereby poor CYP 2C19 * 2 metabolizers ( * 2/ * 2 homozygotes) have poorer platelet inhibition compared to intermediate CYP 2C19 * 2 metabolizers ( * 1/ * 2 heterozygotes) [18] . Genetic analysis of 162 healthy volunteers demonstrated intermediate metabolizers and poor metabolizers to have 26-31% and 46-55% lower clopidogrel metabolite exposure, respectively, compared to noncarriers [19] .
In patients with cardiovascular disease but without having received endovascular treatment, there is little influence of the CYP 2C19 * 2 genotype on the clinical outcome [20] . Parè et al. [20] performed a genetic subanalysis on 2,549 patients randomly assigned clopidogrel and 2,510 assigned placebo (both in combination with aspirin) who were enrolled into the CURE or ACTIVE A trial. It was determined that clopidogrel addition to aspirin was superior to placebo in preventing recurrent ischemic events and Parè et al. [20] concluded that this benefit was not attenuated by the CYP 2C19 genotype. However, these results are in contrast to reports in patient populations undergoing PCI. Mega et al. [19] carried out a genetic substudy of 1,477 patients enrolled into the TRITON-TIMI 38. They reported carriage of the CYP 2C19 * 2 polymorphism to be associated with a 53% increase in poor cardiovascular outcomes, and in the subgroup undergoing PCI a 3-fold increase in stent thrombosis compared to noncarriers (2.6 vs. 0.8%, HR for carriers = 3.09, 95% CI 1.19-8, p = 0.02) was found [19] . These findings are reflective of a number of cohort and case-control studies suggesting that carriage of the CYP 2C19 * 2 polymorphism is associated with an increased risk of ischemic events, including stent thrombosis, in clopidogreltreated patients undergoing PCI [21] [22] [23] . In addition, a meta-analysis of 9 trials evaluating the CYP 2C19 genotype on clinical outcomes in clopidogrel-treated patients revealed an increased risk of stent thrombosis in carriers of both 1 (HR 2.67; 95% CI 1.69-4.22; p ! 0.0001) and 2 (HR 3.97; 95% CI 1.75-9.02; p = 0.001) CYP 2C19 * 2 polymorphisms compared to noncarriers [24] .
Recent studies have focused on the clinical outcomes of Asian patients who carry CYP 2C19 * 2 polymorphisms. Following 1,738 Chinese patients with coronary artery disease (CAD) and undergoing PCI, Luo et al. [25] found carriage of the CYP 2C19 * 2 polymorphism to be an independent predictor of stent thrombosis (HR for carriers = 4.26, 95% CI 1.28-9.22, p ! 0.05). A small study of Japanese patients (n = 100) receiving a DES found the incidence of stent thrombosis but not of major adverse cardiac events to be significantly higher in carriers of the CYP 2C19 * 2 polymorphism compared to noncarriers (52.3 vs. 15.5%, p = 0.0002) [26] .
To our knowledge, no studies have associated CYP 2C19 * 2 polymorphisms and clinical outcomes in a patient population undergoing neurointerventional procedures. However, it follows that, in clopidogrel-treated patients, carriers of the CYP 2C19 * 2 polymorphisms may be at a heightened risk of stent thrombosis following neurointerventional procedures.
The Food and Drug Administration Clopidogrel Black Box Warning
In response to the evidence of reduced efficacy of clopidogrel in patients with CYP 2C19 * 2 polymorphisms, the US Food and Drug Administration (FDA) issued a boxed warning in March 2010 recommending physicians consider alternative management strategies in patients with the poor metabolizer genotype ( * 2/ * 2 homozygotes) (www.fda.gov). Controversially, the warning did not make note of the evidence suggesting that intermediate metabolizers ( * 1/ * 2 heterozygotes) may also have reduced clopidogrel efficacy. The warning focused on a crossover study of 40 healthy volunteers, which demonstrated decreased metabolite exposure and increased platelet aggregation in poor metabolizers following both standard and double dose clopidogrel regimens.
Given the evidence supporting the impact of CYP 2C19 * 2 on clopidogrel responsiveness and clinical outcomes, we believe that it is reasonable to recommend the genotype testing in patients planned for neurointervention procedures. In the following section, we will outline the different management strategies.
Management Strategies for Patients with the CYP 2C19 * 2 Polymorphism
Increased Dosage of Clopidogrel?
There is evidence that improved platelet inhibition could be achieved by increased doses of clopidogrel in patients with CYP 2C19 * 2 demonstrating clopidogrel hyporesponsiveness. Fontana et al. [27] measured platelet function in 81 patients who had recently undergone PCI and had been taking 75 mg clopidogrel daily for 15 days. The patients diagnosed as hyporesponders (55.6%) were changed to 150 mg/day clopidogrel and experienced a decrease in mean platelet reactivity from 62 to 49.4% after 15 days (p ! 0.001). Furthermore, results from the PRINC trial examined the effect of differing clopidogrel regimens on platelet inhibition in patients undergoing PCI [28] . A second 600-mg loading dose 2 h after the first produced better acute platelet inhibition (42% inhibition with clopidogrel vs. 24% with placebo). The trial also demonstrated that an increased maintenance dose of 150 mg produced superior platelet inhibition after 1 week compared to 75 mg in clopidogrel hyporesponders [28] .
However, it remains to be demonstrated that increased doses of clopidogrel achieve superior platelet inhibition and improved clinical outcomes in carriers of the CYP 2C19 * 2 polymorphism.
Alternatives to Clopidogrel
Alternative thiopyridine agents such as prasugrel and ticagrelor have been considered in patients with poor response to clopidogrel. Prasugrel, requiring reduced hepatic conversion in comparison to clopidogrel, appears to have few hyporesponders and produces superior platelet inhibition in comparison to 75 or 150 mg clopidogrel [29] . However, it is noted that prasugrel has an increased bleeding risk compared to clopidogrel and is therefore unlikely to be an appropriate alternative in patients with ischemic stroke [14] . Ticagrelor, although not yet approved for clinical use, does not require hepatic biotransformation. It is seen to be effective in reducing the risk of vascular death, MI, stroke, and stent thrombosis without an increased bleeding risk [14] . Furthermore, ticagrelor appears to be effective in improving platelet inhibition in clopidogrel hyporesponders [30] . Another alternative management strategy under investigation is the addition of a third antiplatelet agent to aspirin and clopidogrel in patients who are seen to be hyporesponsive on tests of platelet function. Addition of cilostazol (100 mg twice daily) to standard clopidogrel and aspirin therapy in patients with clopidogrel hyporesponsiveness provided a greater degree of platelet inhibition compared to high dose clopidogrel in hyporesponsive patients undergoing PCI [14] .
However, both prasugrel and ticagrelor are yet to be validated as superior therapies in CYP 2C19 * 2 poor and intermediate metabolizers.
Currently, there are no prospective trials demonstrating a superior benefit of targeted treatment for patients undergoing interventional procedures based on the CYP 2C19 genotype. The GeCCO (genotype-guided comparison of clopidogrel and prasugrel outcomes study) is the largest open-label cohort study planned to investigate the efficacy of a genotypeguided comparison of therapies based on the CYP 2C19 genotype [14] . The study aims to recruit 14,600 subjects and compare the outcomes of patients assigned to 75 mg clopidogrel or 5-10 mg prasugrel based on genotype. The ACCEL-2C19 study plans to randomly assign 80 patients with stable CAD undergoing PCI to receive high dose clopidogrel (150 mg) plus 100 mg aspirin or cilostazol 100 mg twice daily based on the CYP 2C19 genotype [14] . Additionally, they will measure platelet responsiveness at 30 days.
Platelet function testing is another means of guiding therapy. In contrast to genotypebased assays, platelet function assays are available as convenient point-of-care devices; however, they lack specificity. The largest trial currently examining the efficacy of a phenotypeguided comparison of therapies based on platelet responsiveness to clopidogrel is GRAVI-TAS (gauging responsiveness with a verify now assay -impact on thrombosis and safety) [14] . GRAVITAS aims to recruit 2,800 patients with stable CAD or acute coronary syndrome undergoing PCI with DES placement. Patients with poor platelet inhibition 12-24 h after DES insertion will be randomized to a standard 75 mg or a high dose clopidogrel regimen (an additional 600-mg loading dose followed by 150 mg daily). A substudy of GRAVITAS, GIFT, will aim to assess the association between CYP 2C19 genotype and platelet responsiveness.
Conclusion
A significant proportion of patients undergoing neurointerventional procedures are hyporesponsive to clopidogrel. Carriage of the CYP 2C19 * 2 allele is significantly associated with clopidogrel hyporesponsiveness and poses an increased risk of ischemic events, including stent thrombosis, following PCI. Although these findings remain to be verified in neurointerventional patient populations, CYP 2C19 * 2 screening may form part of neurointerventional practice in the future. Management strategies such as an increased dose of clopidogrel and alternative antiplatelet agents hold promise as viable alternative in patients with clopidogrel hyporesponsiveness but require validation from ongoing trials and in patients with the CYP 2C19 * 2 allele.
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